OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy ...

Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680), for ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton ...

Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...

The high prevalence of anxiety and depression in patients with narcolepsy suggests that a biological relationship is present between the disorders, but larger studies are needed. Sleep disorders are ...

TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house ...